ReMODEL-B: Davies et al. Outstanding e.g. of Cancer Research UK funded RCT using real time GEP COO (+IPI) to stratify+randomise 1L #DLBCL pts btwn RCHOP vs Bortezomib-RCHOP cycle 2 onwards. No diff in PFS but proof of principle truely established. Congratulations to Peter Johnson et al #lymsm

Sibon et al. Pooled analysis 263 ALK+ALCL. In a #lymphoma where RCTs are challenging+with retrospective caveats, this is pretty convincing data (esp<60yr) that argues for adding etoposide in 1L in ALK+ALCL (BV/Echelon-2 aside!). IPI remains strong PFS/OS predictor. #blooducation

Had a great time last night playing some blues and folk tunes with Nobel Laureate cancer researcher/harmonica virtuoso Jim Allison. And yes, a few of the tunes we played came from another Nobelist named Dylan.

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. #lymphoma #lymsm bit.ly/2vWq4Td

Charles Herbaux Graham Collins Toby Eyre John P. Leonard, MD tobiasmenne Jose Sandoval S, MD FACP 🇨🇴🇨🇴 Simon Rule Peter Johnson Jonathan Friedberg Navneet Majhail, MD, MS Shalin Kothari GC-type DLBCL

#ASH19 Jurinovic et al really interesting observation from Gallium study patients with EZH2 mutated FL had much better responses to CHOP based chemo than Benda based suggest R/G CHOP in this setting and R-Benda for non EZH2 mutated FL - needs to be confirmed in other studies

Obinutuzumab and lenalidomide 30mg phase 2 study Nathan Fowler et al • 57 R/r FL 9 all/MZL • good response rates even in rituximab refractory setting •toxicity acceptable •PFS promising Interesting data need to be confirmed in randomised study #ASH19 #lymsm

UK election Conservative party 43.6% of the total UK votes yet they have 55.8% of the seats. How is this democratic!!! Proportional representation is a much fairer system

Great picture

My kids made this just after Easter to thank the EGGcelent NHS. Liked it a lot!

Truly amazing news, Emma!!! Warmest congratulations and cordial wishes for a long and happy life to you all. Very humbled by the honour, Tobias

Great News for UK patients with mantle cell lymphoma Brexucabtagene TECARTUS has been approved by NICE today via CDF

Today we’ve published draft guidance recommending lenalidomide (Revlimid) as the first maintenance treatment for people with newly diagnosed multiple myeloma. Read the draft guidance here: bit.ly/3acjRX3

Will be fascinating to see at ASH. What is OS and PFS difference between R-CHOP and R-CHP+Pola. Ash21 could have several game changers in DLBCL. Polarix for 1L and Transform and Zuma-7 for 2L. Can’t wait to see all these study data.

I am honoured to have been appointed as the new Clinical Director for Research Newcastle Hospitals Newcastle Hospitals Research from September. I will do my utmost best to implement our new strategic priorities to further boost our excellent tradition of Clinical Research at NUTH

Chan Cheah Toby Eyre MarieJosé Kersten NEJM yes me too. I would also caution against the subgroups - confidence intervals well overlapping for each.

Game changing study. E1910. RCT in frontline Ph neg B-ALL addition of blinatumomab consolidation improves significantly OS and EFS in MRD2 neg and positive setting #ASH2022 Blina consolidation should be new SOC

I just attended one of the biggest cancer meetings in the world. #ASH22 ASH For my followers here is a snapshot of the incredible progress happening with cancer treatment. It’s good. Thread.

Please could someone explain the physics behind this phenomena just taken in Tynemouth UK. Not raining anywhere